The most common adverse effects are [[diarrhea]] (4.8%), [[nausea]] and [[vomiting]] (3.6%), injection-site inflammation (2.4%), [[headache]] (2.3%), [[rash]] (1.9%) and [[thrombophlebitis]] (0.9%).<ref name=Mosby/> Many of these adverse effects were observed in severely ill individuals already taking many medications including [[vancomycin]].<ref>{{cite journal|last=Erden|first=M|author2=Gulcan, E |author3=Bilen, A |author4=Bilen, Y |author5=Uyanik, A |author6= Keles, M |title=Pancytopenýa and Sepsýs due to Meropenem: A Case Report|journal=Tropical Journal of Pharmaceutical Research|date=7 March 2013|volume=12|issue=1|doi=10.4314/tjpr.v12i1.21|url=http://www.tjpr.org/vol12_no1/2013_12_1_21.pdf}}</ref><ref>{{cite web|url=http://www.ehealthme.com/meropenem/meropenem-side-effects|title=Meropenem side effects - from FDA reports |publisher=eHealthMe}}</ref>  One study showed ''[[Clostridium difficile colitis|Clostridium difficile]]''-associated [[diarrhea]] <!-- (CDAD) --> happened in 3.6% of meropenem patients.<ref>{{cite journal|last=Yeung|first=EYH|author2=Gore JG |author3=Auersperg EV |title=A Retrospective Analysis of the Incidence of Clostridium Difficile Associated Diarrhea with Meropenem and Piperacillin-tazobactam|journal=International Journal of Collaborative Research on Internal Medicine & Public Health|year=2012|volume=4|issue=8|pages=1567–1576|url=http://www.iomcworld.com/ijcrimph/files/v04-n08-08.pdf}}</ref> Meropenem has a reduced potential for seizures in comparison with [[imipenem]]. Several cases of severe [[hypokalemia]] have been reported.<ref name="pmid17516692">{{cite journal|last=Margolin|first=L|title=Impaired rehabilitation secondary to muscle weakness induced by meropenem|journal=Clinical drug investigation|year=2004|volume=24|issue=1|pages=61–2|doi=10.2165/00044011-200424010-00008|pmid=17516692}}</ref><ref>{{cite journal|last=Bharti|first=R|last2=Gombar|first2=S|last3=Khanna|first3=AK|title=Meropenem in critical care - uncovering the truths behind weaning failure|journal=Journal of Anaesthesiology Clinical Pharmacology|year=2010|volume=26|issue=1|pages=99–101|url=http://www.joacp.org/article.asp?issn=0970-9185;year=2010;volume=26;issue=1;spage=99;epage=101;aulast=Bharti;type=0}}</ref> Meropenem, like other carbopenems, is a potent inducer of multidrug resistance in bacteria.

 

